Indian drug maker Dabur Pharma Ltd said on Saturday its founders and other shareholders have agreed to sell 73.27 percent in the company to Fresenius Kabi (Singapore) Pte Ltd, at 76.50 rupees a share.
The Singapore firm is a unit of European healthcare firm Fresenius SE .
The Indian firm, which makes anti-cancer drugs, had earlier this year denied it was in talks with a German drug maker for a partnership or sale. The deal with Fresenius values it about 10 percent higher from its market capitalisation of $273 million.
Last year, the company had sold its non-oncology drugs business to local rival Alembic to focus on cancer treatment drugs.(Reuters)